Literature DB >> 9699548

Human retinal pigment epithelial cell-induced apoptosis in activated T cells.

A Jørgensen1, A K Wiencke, M la Cour, C G Kaestel, H O Madsen, S Hamann, G M Lui, E Scherfig, J U Prause, A Svejgaard, N Odum, M H Nissen, C Röpke.   

Abstract

PURPOSE: The immune privilege of the eye has been thought to be dependent on physical barriers and absence of lymphatic vessels. However, the immune privilege may also involve active immunologic processes, as recent studies have indicated. The purpose of the present study was to investigate whether human retinal pigment epithelial (RPE) cells can induce apoptosis in activated T cells.
METHODS: Fas ligand (FasL) expression was detected by flow cytometry and immunohistochemistry. Cultured RPE cells were cocultured with T-cell lines and peripheral blood lymphocytes for 6 hours to 2 days. Induction of apoptosis was detected by 7-amino-actinomycin D and annexin V staining.
RESULTS: Retinal pigment epithelial cells expressed FasL and induced apoptosis in activated Fas+ T cells. Blocking of Fas-FasL interaction with antibody strongly inhibited RPE-mediated T-cell apoptosis. Retinal pigment epithelial cells induced apoptosis in several activated T-cell populations and T-cell lines, including T-cell antigen receptor (TCR)-CD3-negative T-cell lines. In contrast, RPE cells induced little or no apoptosis in resting peripheral T cells. Major histocompatibility complex (MHC) class II monoclonal antibodies, which block alloactivation, had no inhibitory effect on RPE-mediated T-cell apoptotic responses in MHC class II-specific CD4+ T-cell lines.
CONCLUSIONS: Retinal pigment epithelial cells express FasL and induce TCR-independent apoptosis in activated human T cells through Fas-FasL interaction. Retinal pigment epithelial cells may constitute an immunologic functional barrier against potentially harmful T cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699548

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

Review 1.  Major histocompatibility complex molecules on parenchymal cells of the target organ protect against autoimmune disease.

Authors:  Hui Shao; Henry J Kaplan; Deming Sun
Journal:  Chem Immunol Allergy       Date:  2007

Review 2.  Age-related macular degeneration: epidemiology and optimal treatment.

Authors:  Morten la Cour; Jens Folke Kiilgaard; Mogens Holst Nissen
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  Targeting immune privilege to prevent pathogenic neovascularization.

Authors:  Jayeeta Roychoudhury; John M Herndon; Jiyi Yin; Rajendra S Apte; Thomas A Ferguson
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-02-17       Impact factor: 4.799

4.  Subcellular distribution and activity of mechanistic target of rapamycin in aged retinal pigment epithelium.

Authors:  Bo Yu; Pei Xu; Zhenyang Zhao; Jiyang Cai; Paul Sternberg; Yan Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-09       Impact factor: 4.799

5.  The immune privileged retina mediates an alternative activation of J774A.1 cells.

Authors:  Chun H Lau; Andrew W Taylor
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

6.  Retinal pigment epithelial cells phagocytosis of T lymphocytes: possible implication in the immune privilege of the eye.

Authors:  F Willermain; L Caspers-Velu; B Nowak; P Stordeur; R Mosselmans; I Salmon; T Velu; C Bruyns
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

7.  The retinal pigment epithelium (RPE) induces FasL and reduces iNOS and Cox2 in primary monocytes.

Authors:  Christin Hettich; Sebastian Wilker; Rolf Mentlein; Ralph Lucius; Johann Roider; Alexa Klettner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-25       Impact factor: 3.117

8.  γδ T cells as a major source of IL-17 production during age-dependent RPE degeneration.

Authors:  Zhenyang Zhao; Pei Xu; Zuliang Jie; Yiqin Zuo; Bo Yu; Lynn Soong; Jiaren Sun; Yan Chen; Jiyang Cai
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

Review 9.  Spheramine for treatment of Parkinson's disease.

Authors:  Natividad P Stover; Ray L Watts
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

10.  Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.

Authors:  Susie E Barker; Cathryn A Broderick; Scott J Robbie; Yanai Duran; Mythili Natkunarajah; Prateek Buch; Kamaljit S Balaggan; Robert E MacLaren; James W B Bainbridge; Alexander J Smith; Robin R Ali
Journal:  J Gene Med       Date:  2009-06       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.